380 related articles for article (PubMed ID: 24107823)
1. [First Hungarian experience with pazopanib therapy for patients with metastatic renal cancer].
Maráz A; Bodrogi I; Csejtei A; Dank M; Géczi L; Küronya Z; Mangel L; Petrányi A; Szûcs M; Bodoky G
Magy Onkol; 2013 Sep; 57(3):173-6. PubMed ID: 24107823
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a single institution experience.
Matrana MR; Bathala T; Campbell MT; Duran C; Shetty A; Teegavarapu P; Kalra S; Xiao L; Atkinson B; Corn P; Jonasch E; Tannir NM
BJU Int; 2016 Aug; 118(2):264-71. PubMed ID: 26573089
[TBL] [Abstract][Full Text] [Related]
3. Experience with pazopanib in the treatment of metastatic renal cell carcinoma: a monocentric experience.
Gernone A
Tumori; 2014; 100(4):165e-8e. PubMed ID: 25296611
[TBL] [Abstract][Full Text] [Related]
4. A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma.
Kim MJ; Park SH; Lee JL; Lee SH; Lee SJ; Lim HY
BMC Urol; 2016 Aug; 16(1):46. PubMed ID: 27484998
[TBL] [Abstract][Full Text] [Related]
5. Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma: a Sarah Cannon Oncology Research Consortium Phase II Trial.
Hainsworth JD; Rubin MS; Arrowsmith ER; Khatcheressian J; Crane EJ; Franco LA
Clin Genitourin Cancer; 2013 Sep; 11(3):270-5. PubMed ID: 23665131
[TBL] [Abstract][Full Text] [Related]
6. First-line pazopanib in intermediate- and poor-risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial.
Staehler M; Panic A; Goebell PJ; Merling M; Potthoff K; Herrmann E; de Geeter P; Vannier C; Hogrefe C; Marschner N; Grünwald V
Int J Cancer; 2021 Feb; 148(4):950-960. PubMed ID: 32738823
[TBL] [Abstract][Full Text] [Related]
7. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.
Sternberg CN; Hawkins RE; Wagstaff J; Salman P; Mardiak J; Barrios CH; Zarba JJ; Gladkov OA; Lee E; Szczylik C; McCann L; Rubin SD; Chen M; Davis ID
Eur J Cancer; 2013 Apr; 49(6):1287-96. PubMed ID: 23321547
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.
Xie M; He CS; Huang JK; Lin QZ
Eur J Cancer; 2015 Mar; 51(5):595-603. PubMed ID: 25618828
[TBL] [Abstract][Full Text] [Related]
9. Pazopanib after sunitinib failure in patients with metastatic renal cell carcinoma.
Rautiola J; Utriainen T; Peltola K; Joensuu H; Bono P
Acta Oncol; 2014 Jan; 53(1):113-8. PubMed ID: 23721300
[TBL] [Abstract][Full Text] [Related]
10. An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma.
Sternberg CN; Davis ID; Deen KC; Sigal E; Hawkins RE
Oncology; 2014; 87(6):342-50. PubMed ID: 25227656
[TBL] [Abstract][Full Text] [Related]
11. Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?
Grassi P; Verzoni E; Ratta R; Porcu L; Prisciandaro M; Mennitto A; Calareso G; de Braud F; Procopio G
Drugs R D; 2017 Sep; 17(3):461-467. PubMed ID: 28801802
[TBL] [Abstract][Full Text] [Related]
12. Pazopanib for Metastatic Renal Cell Carcinoma: A Registry-based Analysis of 426 Patients.
Poprach A; Fiala O; Chloupkova R; Melichar B; Lakomy R; Petrakova K; Zemanova M; Kopeckova K; Slaby O; Studentova H; Kopecký J; Kiss I; Finek J; Dusek L; Buchler T
Anticancer Res; 2018 Jan; 38(1):449-456. PubMed ID: 29277808
[TBL] [Abstract][Full Text] [Related]
13. First-Line and Sequential Use of Pazopanib Followed by Mammalian Target of Rapamycin Inhibitor Therapy Among Patients With Advanced Renal Cell Carcinoma in a US Community Oncology Setting.
Vogelzang NJ; Hackshaw MD; Hutson TE; Bhowmik D; Yap M; Rembert D; Jonasch E
Clin Genitourin Cancer; 2015 Jun; 13(3):210-7. PubMed ID: 25498215
[TBL] [Abstract][Full Text] [Related]
14. [Experience with everolimus therapy for patients with metastatic renal cancer in Hungary].
Maráz A; Bodoky G; Dank M; Géczi L; Kahán Z; Mangel L; Révész J; Szűcs M
Magy Onkol; 2014 Mar; 58(1):4-9. PubMed ID: 24712001
[TBL] [Abstract][Full Text] [Related]
15. Cardiac metastasis from renal cell carcinoma successfully treated with pazopanib: impact of TKIs' antiangiogenic activity.
Schinzari G; Monterisi S; Signorelli D; Cona MS; Cassano A; Danza F; Barone C
Tumori; 2014; 100(6):e298-300. PubMed ID: 25688515
[TBL] [Abstract][Full Text] [Related]
16. Prospective observational study on Pazopanib in patients treated for advanced or metastatic renal cell carcinoma in countries in Asia Pacific, North Africa, and Middle East regions: PARACHUTE study.
Erman M; Biswas B; Danchaivijitr P; Chen L; Wong YF; Hashem T; Lim CS; Karabulut B; Chung HJ; Chikatapu C; Ingles S; Slimane K; Kanesvaran R
BMC Cancer; 2021 Sep; 21(1):1021. PubMed ID: 34521387
[TBL] [Abstract][Full Text] [Related]
17. Persistence and compliance with pazopanib in patients with advanced renal cell carcinoma within a U.S. administrative claims database.
Hackshaw MD; Nagar SP; Parks DC; Miller LA
J Manag Care Spec Pharm; 2014 Jun; 20(6):603-10. PubMed ID: 24856598
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies.
Matrana MR; Duran C; Shetty A; Xiao L; Atkinson BJ; Corn P; Pagliaro LC; Millikan RE; Charnsangave C; Jonasch E; Tannir NM
Eur J Cancer; 2013 Oct; 49(15):3169-75. PubMed ID: 23810246
[TBL] [Abstract][Full Text] [Related]
19. Initial experience with first-line pazopanib in the treatment of metastatic renal cell carcinoma: A single institution data.
Joshi A; Agarwala V; Ramaswamy A; Noronha V; Patil VM; Menon S; Popat P; Sable N; Prabhash K
Indian J Cancer; 2016; 53(4):575-578. PubMed ID: 28485355
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of patients with metastatic renal cell carcinoma treated with pazopanib in daily clinical practice: a single institution experience.
Ricotta R; Di Bella S
Tumori; 2014; 100(3):e87-91. PubMed ID: 25076258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]